Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Trovagene Oncology Company Overview - January 2019
January 29, 2019 -
March 29, 2019

Dr. Thomas Adams, CEO and Chairman, and Dr. Mark Erlander, CSO, will present an overview of Trovagene Oncology and provide an update on the clinical development program with Onvansertib. Onvansertib is a first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor that is being developed for the treatment of leukemias, lymphomas and solid tumor cancers. Currently, we have 3 clinical trails ongoing: a Phase 1b/2 study of Onvansertib in combination with either low-dose cytarabine or decitabine to treat patients with relapsed or refractory Acute Myeloid Leukemia (AML); a Phase 2 study of Onvansertib in combination with Zytiga to treat patients with metastatic Castration-Resistant Prostate Cancer (mCRPC); and a Phase 1b/2 study of Onvansertib in combination with FOLFIRI and Avastin to treat patients with metastatic Colorectal Cancer (mCRC). The webcast of the presentation will be available on Tuesday, January 29th, 2019 http://noble.mediasite.com/Mediasite/Play/f81fbc9ebd8c447f9d650619ae7adee71d